CLINICAL TRIALS (FOR TENNESSEE ONLY)

Guideline Number: CS018TN.M  Effective Date: August 1, 2019

Table of Contents  Page
APPLICATION ................................................. 1  Commercial Policy
COVERAGE RATIONALE ................................ 1  • Clinical Trials
DEFINITIONS .................................................. 3
APPLICABLE CODES ........................................... 3
REFERENCES .................................................... 4
GUIDELINE HISTORY/REVISION INFORMATION ...... 5
INSTRUCTIONS FOR USE ................................... 5

APPLICATION

This Coverage Determination Guideline only applies to the state of Tennessee.

COVERAGE RATIONALE

Indications for Coverage

I. Approved Clinical Trial
   A. An “Approved Clinical Trial” is defined as:
      1. Phase I, Phase II, Phase III, or Phase IV clinical trial;
      2. Being conducted in relation to the prevention, detection or treatment for cancer or other life threatening disease or condition; and
      3. Meets the requirements under Section II below.
      For purposes of this benefit, a “life-threatening disease or condition” is one from which the likelihood of death is probable unless the course of the disease or condition is interrupted.
   B. Additional Clinical Trials:
      Coverage of Routine Patient Costs incurred by members participating in the following types of Clinical Trials is not currently mandated by PPACA. However, UnitedHealthcare’s standard Clinical Trial benefit would also include coverage of the Routine Patient Costs when a member is participating in a:
      1. Phase I, Phase II or Phase III Clinical Trial;
      2. Being conducted in relation to the detection or treatment of non-life threatening:
         a. Cardiovascular disease (cardiac/stroke);
         b. Surgical musculoskeletal disorders of the spine, hip and knees; and/or
         c. Other Clinical Trials: Certain plans may allow Clinical Trials relating to other diseases or disorders which are not life-threatening.
      3. Meets the requirements under Section II below.

II. Criteria For Approved Clinical Trials
   A. The Clinical Trial must be described in paragraph 1, 2 or 3 below.
      1. The study or investigation is approved or funded (which may include funding through in-kind contributions) by one or more of the following:
         a. National Institutes of Health (NIH) [includes National Cancer Institute (NCI)]
         b. Centers for Disease Control and Prevention (CDC)
         c. Agency for Healthcare Research and Quality (AHRQ)
         d. Centers for Medicare and Medicaid Services (CMS)
         e. A cooperative group or center of any of the entities described above or the Department of Defense (DOD) or the Veterans Administration (VA)
         f. A qualified non-governmental research entity identified in the guidelines issued by the National Institutes of Health for center support grants
g. The Department of Veterans Affairs, the Department of Defense or the Department of Energy as long as the study or investigation has been reviewed and approved through a system of peer review that is determined by the Secretary of Health and Human Services to meet both of the following criteria:
   i. Comparable to the system of peer review of studies and investigations used by the National Institutes of Health
   ii. Ensures unbiased review of the highest scientific standards by qualified individuals who have no interest in the outcome of the review; or

2. The study or investigation is conducted under an investigational new drug application reviewed by the U.S. Food and Drug Administration; or
3. The study or investigation is a drug trial that is exempt from having such an investigational new drug application.

B. Additional Requirements:
   1. The clinical trial must have a written protocol that describes a scientifically sound study that has been approved by all relevant institutional review boards (IRBs) before participants are enrolled in the trial. We may, at any time, request documentation about the trial.
   2. The subject or purpose of the trial must be the evaluation of an item or service that meets the definition of a Covered Health Care Service and is not otherwise excluded under the Policy.

III. Qualified Individual
A. A qualified individual must be:
   1. Covered under the health plan; and
   2. Eligible to participate in an approved clinical trial according to the trial protocol when the individual:
      a. Was referred to the clinical trial by an in-network health care professional who has concluded that the individual’s participation would be appropriate because the individual is eligible for the trial according to its protocol; or
      b. Provides the plan with medical and scientific information that establishes that participation would be appropriate because the individual is eligible for the trial according to its protocol.

IV. Routine Patient Costs During Clinical Trials Include Covered Health Care Services:
A. For which benefits are typically provided absent a clinical trial.
B. Required solely for:
   1. The provision of the Experimental or Investigational Service(s) or item (e.g., the infusion administration services to deliver an investigational drug); and/or
   2. The clinically appropriate monitoring of the effects of the service or item (e.g., lab tests and imaging done at a frequency consistent with signs and symptoms and other standards of care for that diagnosis or treatment type); and/or
   3. The prevention of complications.
C. Needed for reasonable and necessary care arising from the provision of Experimental or Investigational Service(s) or item.

Network Plans
If one or more network providers are participating in a clinical trial, then UnitedHealthcare may require that the Qualified Individual participate in the clinical trial using a network provider, as long as the network provider will accept the qualifying individual as a participant in the trial. However, if an Approved Clinical Trial is conducted outside of the Qualified Individual’s state of residence, then UnitedHealthcare may not deny or otherwise limit payment for Routine Patient Services solely on the basis that the trial is conducted out-of-state.

Coverage Limitations and Exclusions
Benefits for Clinical Trials do not include:
- The Experimental or Investigational Service(s) or item that is used in the clinical trial is not covered, except for the following:
  o Certain Category B Devices
  o Certain promising interventions for members with terminal illnesses
  o Other items and services that, in our determination, meet specified criteria in accordance with our medical and drug policies
- Items and services provided solely to satisfy data collection and analysis needs and that are not used in the direct clinical management of the member. Examples include, but are not limited to:
  o Laboratory tests and imaging studies done at a frequency dictated by the study protocol and not consistent with signs and symptoms and other standards of care for that diagnosis or treatment type.
- A service that is clearly inconsistent with widely accepted and established standards of care for a particular diagnosis.
- Items and services provided by the research sponsors free of charge for any person enrolled in the trial.
- Travel and transportation expenses are excluded from coverage. These include, but are not limited to:
  - Fees for all types of transportation. Examples include, but are not limited to: personal vehicle, taxi, medical van, ambulance, commercial airline, and train.
  - Rental car expenses
  - Mileage reimbursement for driving a personal vehicle
  - Lodging
  - Meals
- Routine patient costs obtained out-of-network where non-network benefits do not exist under the plan.
- Clinical Trials that do not meet the requirements listed in the Indications for Coverage section above. An example includes, but is not limited to, Phase 0 drug Clinical Trials.

**DEFINITIONS**

Please check the definitions within the member benefit plan document that supersede the definitions below.

**Category B Devices**: As determined by the FDA, non-experimental and/or investigational devices where the incremental risk is the primary risk in question (i.e., underlying questions of safety and effectiveness of that device type have been resolved), or it is known that the device type can be safe and effective because, for example, other manufacturers have obtained FDA approval for that device type. Only certain FDA-designated Category B Devices are covered. In order to be covered, all of the following criteria must be met:

- The device must be used within the context of an FDA-approved clinical trial.
- The device must be used according to the clinical trial's approved protocols.
- Must fall under a covered benefit category and must not be excluded by law, regulation or current Medicare coverage guidelines.
- The device is medically necessary for the member, and the amount, duration and frequency of use or application of the service is medically appropriate.
- The device is furnished in a setting appropriate to the member's medical needs and condition.

**Clinical Trials/Studies Involving Investigational New Drugs**: (National Institutes of Health) ([https://clinicaltrials.gov/ct2/about-studies/home](https://clinicaltrials.gov/ct2/about-studies/home) – About Clinical Studies > Glossary of Common Site Terms > P)

- **Phase 0**: Exploratory study involving very limited human exposure to the drug, with no therapeutic or diagnostic goals (for example, screening studies, microdose studies).
- **Phase 1**: Studies that are usually conducted with healthy volunteers and that emphasize safety. The goal is to find out what the drug's most frequent and serious adverse events are and, often, how the drug is metabolized and excreted.
- **Phase 2**: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition). For example, participants receiving the drug may be compared with similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.
- **Phase 3**: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
- **Phase 4**: Studies occurring after the US Food and Drug Administration (FDA) has approved a drug for marketing. These include post-market requirement and commitment studies that are required of or agreed to by the sponsor. These studies gather additional information about a drug's safety, efficacy, or optimal use.

**Experimental or Investigational Service(s)**: Medical, surgical, diagnostic, psychiatric, mental health, substance related and addictive disorders or other health care services, technologies, supplies, treatments, procedures, drug therapies, medications or devices that, at the time we make a determination regarding coverage in a particular case, are determined to be any of the following:

- Not approved by the U.S. Food and Drug Administration (FDA) to be lawfully marketed for the proposed use and not identified in the American Hospital Formulary Service or the United States Pharmacopoeia Dispensing Information as appropriate for the proposed use.
- Subject to review and approval by any institutional review board for the proposed use. (Devices which are FDA approved under the Humanitarian Use Device exemption are not Experimental or Investigational.)
- The subject of an ongoing clinical trial that meets the definition of a Phase I, II or III clinical trial set forth in the FDA regulations, regardless of whether the trial is actually subject to FDA oversight.

**APPLICABLE CODES**

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not
Clinical Trials (for Tennessee Only)

**Coding Clarification**: Clinical Trials claims are not limited to these modifiers. However, if a claim has one of these modifiers it is considered to be a Clinical Trials claim.

<table>
<thead>
<tr>
<th>Modifier Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q0</td>
<td>Investigational clinical service provided in a clinical research study that is in an approved clinical research study</td>
</tr>
<tr>
<td>Q1</td>
<td>Routine clinical service provided in a clinical research study that is in an approved clinical research study</td>
</tr>
</tbody>
</table>

**HCPCS Code**

<table>
<thead>
<tr>
<th>Covered When Criteria Are Met</th>
</tr>
</thead>
<tbody>
<tr>
<td>G0276</td>
</tr>
<tr>
<td>G0293</td>
</tr>
<tr>
<td>G0294</td>
</tr>
<tr>
<td>G2000</td>
</tr>
<tr>
<td>S9988</td>
</tr>
<tr>
<td>S9990</td>
</tr>
<tr>
<td>S9991</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Not Covered</th>
</tr>
</thead>
<tbody>
<tr>
<td>S9992</td>
</tr>
<tr>
<td>S9994</td>
</tr>
<tr>
<td>S9996</td>
</tr>
</tbody>
</table>

**Coding Clarification**: Clinical Trials claims are not limited to this diagnosis code. However, if a claim has this code it is considered to be a Clinical Trials claim.

<table>
<thead>
<tr>
<th>ICD-10 Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z00.6</td>
<td>Encounter for examination for normal comparison and control in clinical research program</td>
</tr>
</tbody>
</table>

**REFERENCES**


GUIDELINE HISTORY/REVISION INFORMATION

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/01/2019</td>
<td>Coverage Rationale</td>
</tr>
<tr>
<td></td>
<td>• Simplified content (no change to guidelines)</td>
</tr>
<tr>
<td></td>
<td>Applicable Codes</td>
</tr>
<tr>
<td></td>
<td>• Not covered HCPCS codes: Removed G9057</td>
</tr>
<tr>
<td></td>
<td>Supporting Information</td>
</tr>
<tr>
<td></td>
<td>• Archived previous policy version CS018TN.L</td>
</tr>
</tbody>
</table>

INSTRUCTIONS FOR USE

This Coverage Determination Guideline provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this guideline, please check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Coverage Determination Guideline is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The UnitedHealthcare Coverage Determination Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.